General Information of Drug Combination (ID: DC1L534)

Drug Combination Name
DFN-15 Terameprocol
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Terameprocol   DMC3P45
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: HCC-2998
Zero Interaction Potency (ZIP) Score: 1.36
Bliss Independence Score: 2.88
Loewe Additivity Score: 2.47
LHighest Single Agent (HSA) Score: 1.4

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of DFN-15
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 3 [2]
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DC17SWV U251 Investigative [4]
Clear cell renal cell carcinoma DCUYSN2 A498 Investigative [4]
Glioma DCORIMS SF-539 Investigative [4]
Adenocarcinoma DCU5KYI NCIH23 Investigative [1]
Lung adenocarcinoma DC4NDKD MDA-MB-231 Investigative [1]
Pleural epithelioid mesothelioma DC69APN NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.